Calidi presents positive preclinical data on CLD-401 at SITC; IND filing expected by end 2026

Calidi Biotherapeutics, Inc.

CLD-401 protected from immune clearance and replicates specifically in tumor cells after systemic administration.
Systemic CLD-401 achieves tumor IL-15 superagonist levels comparable to localized Anktiva dosing, with minimal systemic exposure.
IND-enabling studies ongoing; IND submission expected by end of 2026.
Company actively seeking strategic partnerships to accelerate clinical development.
Investor day held at SITC featuring experts Dr. Zamarin (Mount Sinai) and Dr. Wrangle (MUSC).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.